OncoMatch/Clinical Trials/NCT05751343
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Is NCT05751343 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TACE-HACI, plus atezolizumab-bevacizumab for hepatocellular carcinoma.
Treatment: TACE-HACI, plus atezolizumab-bevacizumab — Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for those patients is still unknown. This phase 2 clinical trial aims to investigate the objective response rate for unresectable advanced hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage ADVANCED-STAGE
unresectable advanced-stage HCC
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
white blood cell count >3×10^9/L, absolute neutrophil count >1.5×10^9/L, platelet count >10×10^9/L, hemoglobin concentration >85 g/L
Liver function
Child-Pugh A or B liver function
Child-Pugh A or B liver function; adequate hematologic blood counts (white blood cell count >3×10^9/L, absolute neutrophil count >1.5×10^9/L, platelet count >10×10^9/L, hemoglobin concentration >85 g/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify